From: Sputum mediator profiling and relationship to airway wall geometry imaging in severe asthma
 | Total | Low total area | High total area | p value | Low luminal area | High luminal area | p value |
---|---|---|---|---|---|---|---|
N | 59 | 30 | 29 | Â | 30 | 29 | Â |
Male, n | 25 | 12 | 13 | 0.37 | 12 | 13 | 0.37 |
Current age | 49 (2) | 53 (2) | 45 (2) | 0.02 | 53 (2) | 45 (2) | 0.024 |
Age of onset | 28 (2.5) | 34 (3.5) | 21 (3) | 0.037 | 32(3.5) | 22 (3) | 0.041 |
BMI, kg/m2 | 29.8 (0.8) | 32.3 (1.2) | 27.4(1.1) | 0.003 | 32.6 (1.1) | 27.1 (1.1) | 0.001 |
Habitual smokers and ex smokers with >10 py | 13 | 10 | 3 | 0.16 | 9 | 4 | 0.3 |
Pack years history | 8 (2.5) | 11 (5) | 6 (2.5) | 0.36 | 11 (5) | 6 (2.5) | 0.23 |
Severe Exacerbations | 2 | 2 (0.3) | 3 (0.4) | 0.03 | 2 (0.3) | 3 (0.4) | 0.03 |
IgE | 153 [97–241] | 145 [74–183] | 162 [84–313] | 0.87 | 143 [82–325] | 167 [76–270] | 0.89 |
ACQ6 | 2.18 (0.13) | 2.2 (0.17) | 2.14 (0.23) | 0.74 | 2.21 (0.17) | 2.15 (0.23) | 0.76 |
Inhaled Corticosteroid dose | 2000 [400–4000] | 2000 [400–4000] | 2000 [640–4000] | 0.28 | 2000 [400–4000] | 2000 [640–4000] | 0.43 |
Subjects taking oral corticosteroids | 25 | 15 | 10 | 0.72 | 15 | 10 | 0.72 |
Daily prednisolone dose, mg | 4.5 (0.7) | 6 (1.2) | 2.5 (0.7) | 0.54 | 5.5 (1.5) | 3.5 (0.8) | 0.83 |
Pre Bronchodilator FEV1 | 2.26 (0.12) | 2.24 (0.17) | 2.2 (0.16) | 0.9 | 2.18 (0.17) | 2.34 (0.15) | 0.49 |
Pre Bronchodilator FEV1% predicted | 2.42 (0.12) | 2.4 (0.18) | 2.4 (0.16) | 0.98 | 2.33 (0.18) | 2.5 (0.15) | 0.48 |
BD reversibility, ml | 0.23 (0.07) | 0.31 (0.14) | 0.13 (0.03) | 0.23 | 0.29 (0.13) | 0.15 (0.03) | 0.36 |
Pre Bronchodilator FVC | 3.26 (0.1) | 3.22 (0.21) | 3.29 (0.20) | 0.87 | 3.1 (0.22) | 3.3 (0.18) | 0.39 |
Pre Bronchodilator FVC | 3.35 (0.1) | 3.36 (0.21) | 3.32 (0.20) | 0.88 | 3.27 (0.21) | 3.42 (0.18) | 0.61 |
Pre Bronchodilator FEV1% of predicted | 75.2 (3) | 76 (4) | 74.3 (3.6) | 0.79 | 74.3 (5) | 76 (3.4) | 0.77 |
Post Bronchodilator FEV1% of predicted | 80.8 (2.9) | 80.8 (4) | 80.8 (3.4) | 0.99 | 78.4 (5) | 83.1(3.2) | 0.42 |
Bronchodilator Reversibility %FEV1 | 5.9 (0.97) | 5.4 (1.4) | 6.4 (1.7) | 0.58 | 4.7 (0.8) | 7.1 (1.7) | 0.22 |
Pre Bronchodilator FEV1/FVC ratio | 69.5 (1.8) | 69 (2.6) | 69.3 (2.7) | 0.82 | 69.6 (2.4 | 69.4 (2.5) | 0.95 |
Post Bronchodilator FEV1/FVC ratio | 72.1 (1.7) | 78 (2.5) | 72.8 (2.5) | 0.62 | 70.7 (2.4) | 73.4 (2.4) | 0.44 |
Total Cells | 0.5 [0.4-0.8] | 0.6 [0.3-1.1] | 0.5 [0.3-0.8] | 0.61 | 0.6 [0.3-1] | 0.5 [0.3-0.8] | 0.77 |
Neutrophils % | 58.3 [48–69.5] | 55.6 [40.7-76.3] | 60 [50.1-72.6] | 0.97 | 56.2 [47–77] | 59.9 [49.5-72.5] | 0.76 |
Eosinophils % | 2.2 [1.5-3.4] | 2.5 [1.3-4.5] | 2 [1.1-3.7] | 0.43 | 2.2 [1.1-4.2] | 2.2 [1.2-4] | 0.80 |
Bronchiectasis present,% | 23 (39) | 7(30) | 16 (69) | 0.02 | 9 (39) | 14 (60) | 0.16 |
Bronchial Wall Thickening present,% | 39 (67) | 21(53) | 18 (46) | 0.66 | 22 (56) | 17 (43) | 0.22 |
Lumen area/Body Surface Area (mm2/m2) | 5.3 (0.3) | 3.4 (0.2) | 7.2 (0.42) | 0.001 | 3.2 (0.2) | 7.3 (0.4) | 0.001 |
Total area/Body Surface Area (mm2/m2) | 17.8 (0.8) | 12.7 (0.6) | 22.8 (1) | 0.001 | 13.2 (0.8) | 22.3 (0.9) | 0.001 |